These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28545035)

  • 1. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.
    Kim SM; Lee B; An HJ; Kim DH; Park KC; Noh SG; Chung KW; Lee EK; Kim KM; Kim DH; Kim SJ; Chun P; Lee HJ; Moon HR; Chung HY
    Oncotarget; 2017 Jul; 8(28):46273-46285. PubMed ID: 28545035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation.
    An HJ; Lee B; Kim SM; Kim DH; Chung KW; Ha SG; Park KC; Park YJ; Kim SJ; Yun HY; Chun P; Yu BP; Moon HR; Chung HY
    Biol Pharm Bull; 2018; 41(1):29-35. PubMed ID: 29311481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice.
    Kong Q; Zhang H; Zhao T; Zhang W; Yan M; Dong X; Li P
    Int J Mol Med; 2016 Dec; 38(6):1715-1726. PubMed ID: 27840945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis.
    Das KP; Wood CR; Lin MT; Starkov AA; Lau C; Wallace KB; Corton JC; Abbott BD
    Toxicology; 2017 Mar; 378():37-52. PubMed ID: 28049043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.
    Li Y; Chen M; Zhou Y; Tang C; Zhang W; Zhong Y; Chen Y; Zhou H; Sheng L
    Theranostics; 2020; 10(8):3579-3593. PubMed ID: 32206109
    [No Abstract]   [Full Text] [Related]  

  • 14. 2,4-Dihydroxyphenyl-benzo[d]thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS scavenging in the skin.
    Jung HJ; Kim SM; Kim DH; Bang E; Kang D; Lee S; Chun P; Moon HR; Chung HY
    Exp Gerontol; 2021 Jan; 143():111153. PubMed ID: 33189833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
    Yin J; Luo Y; Deng H; Qin S; Tang W; Zeng L; Zhou B
    J Ethnopharmacol; 2014 May; 154(1):229-39. PubMed ID: 24735863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
    Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY
    Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism.
    Yin Y; Yu Z; Xia M; Luo X; Lu X; Ling W
    Eur J Clin Invest; 2012 Nov; 42(11):1189-96. PubMed ID: 22958216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt.
    Jia Y; Wu C; Kim J; Kim B; Lee SJ
    J Nutr Biochem; 2016 Feb; 28():9-18. PubMed ID: 26878778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
    Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
    Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.